Rivastigmine for Intensive Care Unit (ICU) Delirium

PHASE4TerminatedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

May 31, 2010

Conditions
Delirium
Interventions
DRUG

Rivastigmine

Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.

DRUG

Placebo

Placebo, 2 times a day

Trial Locations (6)

7300 DS

Gelre Hospitals; lukas site, Apeldoorn

1800 AM

Medical Center Alkmaar, Alkmaar

8901 BR

Medical Center Leeuwarden, Leeuwarden

3000 CA

Erasmus Medical Center, Rotterdam

3508 GA

University Medical Center Utrecht, Utrecht

3582 KE

Diakonessenhuis, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Novartis

INDUSTRY

collaborator

Netherlands Brain Foundation

OTHER

lead

UMC Utrecht

OTHER